Evidence map›Paper›PMID 34201709›Full record

ReviewBiomedicines2021

Merkel Cell Carcinoma.

Elena Dellambra, Maria Luigia Carbone, Francesca Ricci, Francesco Ricci, Francesca Romana Di Pietro, Gaia Moretta, Sofia Verkoskaia, Elisa Feudi, Cristina M Failla, Damiano Abeni and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Feline Papillomatosis.Viruses · 2025
    Review
  9. Breast skin merkel cell carcinoma: a case report.American journal of translational research · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Elena DellambraMolecular and Cell Biology Laboratory, IDI-IRCCS, 00167 Rome, Italy.ORCID 0000-0002-4329-3312
Maria Luigia CarboneExperimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy.ORCID 0000-0002-3350-1210
Francesca RicciHistopathology Unit, IDI-IRCCS, 00167 Rome, Italy.
Francesco RicciDermatology Department, IDI-IRCCS, 00167 Rome, Italy.
Francesca Romana Di PietroOncology Department, IDI-IRCCS, 00167 Rome, Italy.
Gaia MorettaDermatology Department, IDI-IRCCS, 00167 Rome, Italy.
Sofia VerkoskaiaOncology Department, IDI-IRCCS, 00167 Rome, Italy.
Elisa FeudiExperimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy.
Cristina M FaillaExperimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy.ORCID 0000-0001-5991-8914
Damiano AbeniClinical Epidemiology Unit, IDI-IRCCS, 00167 Rome, Italy.ORCID 0000-0002-0167-7617
Luca FaniaDermatology Department, IDI-IRCCS, 00167 Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Dermopatico dell'Immacolata · IT

Funding

Fondazione Umberto Veronesi Post-doctoral FellowshipsMinistero della Salute RF-2016-02362541Ministero della Salute Ricerca Corrente 2020
6 · The paper itself

Abstract

Merkel cell carcinoma (MCC) is a rare and extremely aggressive neuroendocrine carcinoma of the skin, with increasing incidence worldwide. This review intends to propose a comprehensive evaluation of MCC epidemiology, clinical features, pathogenetic mechanisms, diagnosis, and therapies. A section is dedicated to immunological aspects and another to the involvement of angiogenesis and angiogenic growth factors in MCC progression, proposing novel diagnostic and therapeutic approaches. Advanced MCC tumors have been treated with immune checkpoint inhibitors with effective results. Therefore, the state of art of this immunotherapy is also examined, reporting on the most recent clinical trials in the field. We conclude by underlining the achievements in the understanding of MCC pathology and indicating the present needs for effective diagnosis and therapeutic management of the disease.

Indexed as

immune checkpoint inhibitorsMerkel cell carcinomaMerkel cell polyomavirus

Identifiers

PMID34201709
PMCPMC8301416
OpenAlexW3173687025

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.